One To Watch

Sagimet Biosciences

A clinical-stage biopharma company developing selective fatty acid synthase (FASN) inhibitors for diseases driven by dysregulated lipid metabolism and fibrosis, with current priorities in MASH and acne.

Headquarters and Global Presence

Sagimet is headquartered in San Mateo, California. The company operates as a U.S.-listed public company with clinical and partnering activity spanning the U.S., Asia (via partners) and other trial geographies.

Founding and History

Sagimet was founded to advance small-molecule FASN inhibition into human disease settings where lipid metabolism is implicated in inflammation, fibrosis and sebaceous activity. The company completed an IPO in 2023 and has since concentrated its strategy on advancing denifanstat and building a follow-on FASN inhibitor pipeline.

Therapy Areas and Focus

Sagimet’s development focus is centered on conditions linked to dysfunctional lipid metabolism:

Metabolic liver disease: metabolic dysfunction–associated steatohepatitis (MASH), including patients with moderate-to-advanced fibrosis (F2–F3)
Dermatology: acne vulgaris (commercial and regulatory activity in China is led by partner Ascletis)
The company also positions FASN biology as relevant to other fibrotic and metabolic indications, but public disclosures are most developed around MASH and acne.

Technology Platforms and Modalities

Sagimet is a small-molecule company built around selective inhibition of FASN, a key enzyme in de novo lipogenesis. Lead assets and approaches include:

Denifanstat (formerly TVB-2640): oral, once-daily FASN inhibitor; advanced clinically in MASH and developed in acne through a China license partner
Combination strategy in MASH: denifanstat evaluated alongside resmetirom (Madrigal’s thyroid hormone receptor-β agonist; marketed as Rezdiffra) to explore complementary mechanisms in metabolic liver disease
Next-generation FASN inhibitor: TVB-3567 (IND-cleared program disclosed previously by the company for acne development)

Key Personnel

David Happel: Chief Executive Officer and Director
Thierry Chauche: Chief Financial Officer

Strategic Partnerships

Sagimet’s partnering strategy has been most visible in two areas:

Ascletis (China): license partner developing denifanstat (ASC40) in acne, including Phase III programs and regulatory preparation in China
MASH combination development: clinical work combining denifanstat with resmetirom reflects a strategy to position FASN inhibition within emerging combination regimens in MASH

FAQ Section

Sagimet develops selective FASN inhibitors. The platform thesis is that reducing pathological lipid synthesis can modulate downstream inflammatory and fibrotic pathways in MASH and reduce sebum-linked disease biology in acne.

The company’s current focus is MASH (metabolic liver disease with fibrosis) and acne. These are the two areas where Sagimet has disclosed the most advanced clinical and partner-driven development activity.

Denifanstat: clinical-stage program in MASH, supported by Phase II (FASCINATE-1) and Phase IIb (FASCINATE-2) experience; positioned for later-stage development
Denifanstat in acne: Phase III activity and regulatory progress in China are led by Ascletis under license
TVB-3567: follow-on FASN inhibitor (IND-cleared), positioned for acne development (program details and next steps have been communicated via corporate updates rather than a full public clinical roadmap)

February 2026: Sagimet reported that its China partner disclosed one-year durability/safety results from an open-label extension following a Phase III acne program with denifanstat (ASC40).
January 2026: Sagimet highlighted additional analyses from the Phase IIb FASCINATE-2 program at the MASH-TAG 2026 meeting, focusing on antifibrotic effects in advanced-fibrosis subgroups.
Late 2025 to early 2026: Sagimet advanced its denifanstat–resmetirom combination strategy, including Phase I pharmacokinetic work designed to support subsequent patient studies.

Sagimet’s most substantive clinical evidence base remains denifanstat in MASH, including biopsy-driven Phase IIb work (FASCINATE-2). In acne, recent disclosures have been driven by partner-led Phase III results and longer-duration safety follow-up in China.

Near-term milestones are expected to be program-execution driven:

Next clinical steps in MASH informed by end-of-Phase II regulatory interactions and the company’s combination-development strategy
Further partner-led regulatory progression in China for acne
Readouts and decisions from early clinical work intended to support combination development (as applicable)

Sagimet’s positioning centers on FASN inhibition as a metabolic and antifibrotic lever, and on combination development as a pragmatic route to differentiated clinical utility as MASH treatment paradigms move toward multi-mechanism regimens.

Want to Update your Company's Profile?